Compounds > hydroperoxyisophosphamide
Page last updated: 2024-12-07

hydroperoxyisophosphamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroperoxyisophosphamide: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99769
CHEMBL ID1997458
MeSH IDM0059319

Synonyms (30)

Synonym
nsc-227114
nsc227114
2h-1,2-oxazaphosphorin-2-amine, n,3-bis(2-chloroethyl)tetrahydro-4-hydroperoxy-
mls003389453 ,
NCI60_001854
hydroperoxyisophosphamide
4-hydroperoxyisophosphamide
hydroperoxide, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl-, p-oxide
nsc 207117
asta 6760
nsc-207117
39800-28-7
nsc207117
4-hydroperoxyifosfamide
2h-1,3,2-oxazaphosphorin-2-amine, n,3-bis(2-chloroethyl)tetrahydro-4-hydroperoxy-
smr002049106
nsc 227114
2h-1,3,2-oxazaphosphorin-2-amine, n,3-bis(2-chloroethyl)tetrahydro-4-hydroperoxy-, p-oxide
hydroperoxide, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl, p-oxide
3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-2-oxido-1,3,2-oxazaphosphinan-4-yl hydroperoxide #
YGZIWEZFFBPCLN-UHFFFAOYSA-N
CHEMBL1997458
FT-0707285
cephalexinmonohydrate
3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-4-hydroperoxy-1,3,2lambda~5~-oxazaphosphinan-2-one
DTXSID30960365
n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
PD162207
HY-134228
CS-0139876

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" To investigate its optimal combinations, we studied the effect of 4-hydroperoxy ifosfamide (the active form of ifosfamide) in combination with other anticancer agents against two human cancer cell lines, MG-63 (an osteosarcoma cell line) and MOLT-3 cells (a T-cell leukemia cell line)."( Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines.
Asakura, S; Kano, Y; Suzuki, K; Takagi, T; Yazawa, Y, 1999)		0.3

Dosage Studied

ExcerptRelevanceReference
" The combination treatments with 6-thioguanine and each of six agents, especially with ACNU, showed a distinct therapeutic effect against the early L-1210 leukemia at dosage levels not producing any significant antitumor activity with each agent alone (ip-ip)."( Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
Fujimoto, S; Horikoshi, N; Hoshino, A; Inagaki, J, 1977)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency27.09550.707912.194339.8107AID720542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1132136Acute toxicity in iv dosed Wistar rat1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132169Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132153Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 100 mg/kg, ip administered 24 hrs relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132163Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132143Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 20 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132152Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 50 mg/kg, ip administered 24 hrs relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132164Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132155Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 200 mg/kg, ip administered 24 hrs relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132131Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as maximum tolerated dose for survival over 30 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132144Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 200 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132161Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132129Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132168Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132154Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 20 mg/kg, ip administered 24 hrs relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132142Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 100 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132135Acute toxicity in po dosed BDF1 mouse1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132133Acute toxicity in iv dosed BDF1 mouse1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132162Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132165Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132130Ratio of ILSmax to ILS30 for antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132137Acute toxicity in ip dosed Wistar rat1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132167Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132134Acute toxicity in ip dosed BDF1 mouse1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132128Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 72 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132138Acute toxicity in po dosed Wistar rat1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132166Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID1132141Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 50 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (29.41)18.7374
1990's6 (35.29)18.2507
2000's3 (17.65)29.6817
2010's3 (17.65)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.20 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroacetaldehyde
[no description available]		2.4120organochlorine compound
acetaldehyde
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.		2.4120aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent
ifosfamide
[no description available]		3.99140ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
thymidine
[no description available]		1.9810pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
acrolein
[no description available]		1.9810enalherbicide;
human xenobiotic metabolite;
toxin
improsan
improsan: synonyms NSC-102627, alkylating agent 864 & yoshi 864 refer to HCl; RN given refers to parent cpd; structure		1.9510organosulfonic ester
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		1.9910taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		1.9910beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
isophosphamide mustard
isophosphamide mustard: antitumor metabolite of ifosfamide; palifosfamide-tris is a salt with tris; structure in first source		2.0310phosphorodiamide
aldophosphamide
aldophosphamide: metabolite of cyclophosphamide		2.0310nitrogen mustard
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		1.95102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
perfosfamide
[no description available]		2.1510
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		2.940organosulfonic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.6430
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Leucocythaemia
[description not available]		02.1510
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.1510
Glial Cell Tumors
[description not available]		01.9810
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		01.9810
Cancer of Ovary
[description not available]		01.9910
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9910
Carcinoma, Epidermoid
[description not available]		01.9910
Cancer of Cervix
[description not available]		01.9910
Cancer of Colon
[description not available]		02.4120
Malignant Melanoma
[description not available]		01.9910
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9910
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		01.9910
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4120
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9910